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1. Introduction  
At present, we wonder if the current classification of diabetes agrees with the new advances 
At the molecular genetic level. Every day we can see an exponential increase of type 1 and 2 
diabetes anywhere in the world. On the other hand, although several clinical and 
biochemical characteristics have been described in order to differentiate between both types 
of diabetes, this does not seem satisfactory for all cases when facing the patient. These 
characteristics are: (a) The presence of a strong familiar history of diabetes, obesity, 
acanthosis nigricans, and lack of ketoacidosis and auto-antibodies against antigens of 
pancreatic b-cells islets supports the diagnosis of type 2 diabetes; (b) In contrast, patients 
with type 1 diabetes are usually thin and with ketoacidosis; almost 90% of them have auto-
antibodies at the onset of the disease. 
Nevertheless, in the last decades numerous reports described adults and adolescents 
(usually from minority groups) presenting ketoacidosis with lack of antibodies and 
characteristics of type 2 diabetes such as obesity, acanthosis nigricans and/or one 
significant familiar history of diabetes (Pinhas-Hamiel et al., 1997; Pinhas-Hamiel & 
Zeitler, 1999;).  
Until very recently, most children and adolescents diagnosed with the disease were 
diagnosed as type 1 diabetes; however, there have recently been numerous reports 
describing an increase in the number of cases of type 2 diabetes in youngsters (Dabelea et 
al., 1998; Hathout et al., 2001; Neufeld et al., 1998; Pinhas Hamiel et al., 1996; Scott et al., 
1997). Epidemiological data suggests that type 1 and 2 diabetes can coexist in the same 
family (Kolb & Mandrup-Poulsen, 2005; Libman & Becker, 2003).  
The potential importance of formulating a specific diagnosis has been emphasized, as this 
could determine the type of treatment, associated complications, and outcomes (Fagot et al., 
2001; Pinhas-Hamiel & Zeitler, 1999). The current criteria for defining diabetes (Asociación 
Latinoamericana de Diabetes [ALAD], 2010; American Diabetes Association [ADA], 2010) 
do not always explain neither the evolution of the disease in different patients or the 
different responses of individuals to treatments. These facts are suggesting the importance 
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of considering the genetic background of individuals for their categorization and 
subsequent treatment. A highly controversial topic has recently aroused worldwide: is there 
a new type of diabetes with mixed characteristics of both types? Different authors have 
identified this variety as “Double Diabetes” or “Hybrid Diabetes” (Libman & Becker, 2003; 
Mimbacas et al., 2011; Pozzilli & Buzzetti; 2007; Pozzilli  & Guglielmi., 2007); but, are we 
really facing a new type of diabetes unknown before?, or is it a phenomenon not 
demonstrated until present due to the use of former inappropriate methodologies or 
instrumentations? If it is a new expression, why does it appear now? Is there an 
evolutionary process involved? How? 
We will try to discuss these subjects in this chapter. 
2. Brief history of diabetes mellitus and the evolution of the classification  
In order to understand our point of view we must begin with a brief description of diabetes 
history and classification. The term diabetes (Greek: ) was coined by Aretaues of 
Cappadocia. It is derived from the Greek word , diabaínein that literally means 
"passing through" or "siphon", a reference to one of diabetes' major symptoms—excessive 
urine production. In 1675, Thomas Willis added the word mellitus, from the Latin meaning 
"honey", as a reference to the sweet taste of the urine. Matthew Dobson (1776) confirmed 
that the sweet taste was due to an excess of a kind of sugar in the urine and blood of people 
with diabetes. The ancient Indians tested for diabetes by observing whether ants were 
attracted to a person's urine, and called the ailment "sweet urine disease". The Korean, 
Chinese, and Japanese words for diabetes are based on the same ideographs (糖尿病), which 
mean "sugar urine disease". 
As stated above, although diabetes has been recognized since antiquity, and treatments of 
different efficiencies have been known in several regions since the Middle Ages and for 
much longer in legends, the pathogenesis of diabetes has only been understood 
experimentally since about 1900 (Patlak, 2002a; 2002b). The endocrine role of the pancreas in 
metabolism, and indeed the existence of insulin, was not further clarified until 1922, when 
Banting and Best demonstrated that they could reverse induced diabetes in dogs by giving 
them a pancreatic islets of Langerhans extract of healthy dogs (Banting et al., 1922). 
However the precise molecular mechanism of the disease is just beginning to be unraveled. 
Fortunately, the increasing inventory of human genetic variation is easing our 
understanding of why susceptibility to the common disease varies between individuals and 
populations (Rotimi & Jorde, 2010), as we shall see.  
In terms of classification, the first distinction between different presentations of the disease, 
as it is currently known, was clearly established by Sir H P Himsworth, and published in 
January 1936 (Himsworth, 1936). From its very beginning, the different classifications have 
undergone changes in the attempt to obtain a better adjustment of the organization of 
diabetes’ nosology (Alberti & Zimmet, 1998): (1) Age, which was the main criterion of the 
first classification, was quickly abandoned because the different forms can appear at any 
age, although one is more frequently observed in childhood and youth and the other one in 
adults (at present, type 1 and 2 respectively); (2) Insulin dependence was the new clinical 
criterion taken into consideration, because it was easy to use in clinical practice and allowed 
to consider sub-groups with different pathogenic mechanisms; for several years insulin 
dependence was an indicator of the auto-immune process. 
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Currently, the classification of Diabetes mellitus (ADA, 2010; ALAD, 2010) contemplates 
four well-known major groups: (a) Type 1 Diabetes (T1DM), (b) Type 2 (T2DM), (c) Other 
specific types of diabetes, and (d) Gestational diabetes. 
However, on the basis of clinical observations, genetics and molecular research studies 
carried out in some mixed populations such as those in Latin America (as we shall see 
below) would point out that this classification is not always adequate; phenotype does not 
always reflect genotype (Mimbacas et al., 2009). 
3. Miscegenated population  
In order to support our hypothesis that phenotype is not always a proper indicator of 
genotype, mainly in miscegenated populations (particularly in multifactorial diseases such 
as diabetes), we will focus our analysis on the research carried out in our population. We 
believe that the current classification does not always allow an accurate diagnosis, and 
therefore the treatment plan is not always the correct one. 
Previous research has shown that the Uruguayan population has a particular genetic 
behavior; in addition to its small size (three millions inhabitants), it presents such a high 
level of miscegenation that there are individuals that cannot currently identify their 
ancestors’ origin. It has a tri-hybrid origin (Caucasoid, African and Amerindian) but, unlike 
other Latin-American countries, we do not isolate Amerindian groups (Cardoso et al., 2004; 
Gascue et al., 2005; Mimbacas et al., 2003, 2004, 2007, 2009; Sans et al., 2011). Thus, this 
would permit us to think a priori that ethnological factors would (at least in part) cancel 
each other, therefore eliminating their possible blurring effect on the analysis. When we 
consider these factors, we can look at our population as an interesting source of information 
for the study of different issues on diabetes.  
Several years ago, we focused our investigation on HLA genes associated with type 1 
diabetes; our studies (Mimbacas et al., 2003, 2004) were done both by case-control and 
parent-cases design. We found a very high frequency of specific alleles (DQB1*0201, 
DQB1*0302, DR3, DR4) in our population; although the associated alleles were the same 
as those of the Caucasian population, their frequencies were different; additionally, we 
also found that almost all of the patients had associated DR3 and DR4 alleles. Continuing 
with our investigations, we observed that different polymorphisms of other analyzed 
genes also showed variations when compared with Caucasian populations or with 
populations from other origin (Fernández et al., 2009; Mimbacas et al., 2007; Soto et al., 
2004; Zorrilla et al., 2006). 
Conversely, there have been numerous reports describing an increasing number of type 2 
diabetes cases in youngsters (Dabelea et al., 1998; Neufeld et al., 1998; Pinhas-Hamiel et 
al., 1996; Scott et al., 1997). Recently, Lidman and Becker (2003) described the coexistence 
of types 1 and 2 diabetes in a non-Caucasian individual; afterwards, Pozzili and Buzzetti 
(2007) described more cases and defined the possibility of a new type of diabetes, 
proposing more characterization studies in different ethnic groups. In a recent paper 
(Mimbacas et al., 2011) we described a case report that, according to our criteria, showed 
this type of presentation of the disease. 
In what it has to do with this possibility of a new expression of diabetes, it is important to 
determine the influence of the genetic and auto-immune factors underlying the consequent 
destruction of the beta islets, which would pass unnoticed in a classic phenotype. 
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In the light of an emerging expression of diabetes, and in an attempt to link genetics to the 
clinic, we continued with our research. On the basis of previous findings and in the clinical 
evolution of patients, we began to see that in many cases it was very difficult to classify 
patients into one of the 2 main groups of the current diabetes classification (type 1 or type 2). 
Another associated observation was that, despite following the international protocols, 
patients did not always show a good response to treatment.  
Therefore, we were interested in testing the hypothesis that genotype does not necessarily 
result in the disease phenotype. For this purpose, we proposed to determine whether a 
genetic profile is useful for providing the clinician and the patient with more accurate 
information, not only for knowing the specific type of diabetes, but also to understand the 
hyperglycemia pathogenesis and thus treat it more effectively.  
For five years we examined a dynamic cohort of clinical histories of diabetes’ patients, with 
a follow up of 86.6% (Mimbacas et al., 2009). At first, patients were classified into two 
groups: type 1 diabetes and type 2 diabetes according to the American Diabetes Association 
criteria (ADA, 2004). We analyzed HLADQB1*/DR in all samples and studied the presence 
of autoantibodies glutamic acid decarboxylase (GADA) and islet cell (ICA). We found 
surprising results, specifically in patients diagnosed as type 2 diabetes. When we applied 
the classification grouping the patients as type 1 and type 2 to our data, we found that the 
phenotype was not correlated with the expected data in all cases. In order to improve our 
knowledge of the pathogenesis of hyperglycemia and thus implement a more accurate 
treatment for the patients, we reclassified our sample according to the presence or absence 
of the genetic and immunological markers (Figure 1).  
 
 
Fig. 1. A high percent of type 2 diabetes have HLA susceptibility gene for type 1 diabetes. 
The data obtained shows statistical significant differences, implying that the clinical 
classification is probably not discriminatory enough for an accurate classification of different 
types of diabetes (Mimbacas et al., 2009). The methodology implemented in this 
investigation permitted us to establish that the phenotypic classification did reflect neither 
the genetic profile nor the immunological disease. The genetic data can help us to provide 
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an accurate definition of the disease, and would therefore give the physician a better 
possibility of providing an adequate treatment. 
Today, a proper differentiation between the different types of diabetes is becoming an 
increasingly challenging task. The effect of genetic variables on diabetes has been studied 
for several decades, but there are only a few consistent risk factors identified up to date.  
Most of the large scale studies on candidate genes for diabetes published so far have not 
performed a combined analysis of both types of diabetes; moreover, there are a high number 
of published papers dealing with this subject but whose populations are not admixed like 
the Uruguayan one. Thus, we consider that the Uruguayan population is an interesting one 
to accomplish epidemiological studies, and that it will therefore contribute to the discussion.  
Unfortunately, currently there are a very few researchers using new advanced 
methodology, such as genome wide association, in non-Caucasian population; nearly 90% of 
genome scan studies have been carried out in populations of European ancestry (Rotimi & 
Jorde, 2010). 
4. Overweight and obesity mask a genetic profile associated to type 1 
diabetes  
As stated above, once diabetes diagnosed, proper classification is the first difficulty of this 
disease in clinical practice, as future treatment will depend on this. This is partly due to a 
lack of correlation between phenotype and genotype, and to the possible existence of a new 
form of diabetes, or a different expression, called "hybrid or double". This may pass 
inadvertently if the corresponding genetic and immunological analyses are not carried out. 
Overweight or obesity is one phenotypic trait that is part of the definition of type 2 diabetes. 
In our study (Mimbacas et al., 2009) we observed that many patients clinically diagnosed as 
type 2 with positive HLA show overweight or obesity; we therefore suggested looking for a 
genetic explanation for this apparent contradiction. Overweight or obesity is indicative of 
insulin-resistance. The primary disorder type 2 diabetes is considered as an insulin-resistant 
one with an increase in insulin secretion and a decrease in beta cell secretion after several 
years (Ruiz, 2011).  
On the other hand, the importance of a study on insulin resistance lies in the fact that the 
underlying process would be a cardiovascular risk factor per se (Howard et al., 1996; Yip 
et al., 1998).  
Despite evidence of a genetic influence, bibliography suggests that the genetic contribution 
to insulin resistance is the result of several gene variants that are relatively common in the 
population, each one with only a moderate influence, but with much more stronger effects 
when they interact. The heterogeneous and polygenic nature of insulin resistance has made 
the identification of these gene variants a challenging task. However, once these insulin-
resistance susceptibility gene variants are identified, they will have far-reaching 
implications for our comprehension of the molecular and pathophysiologic basis of insulin 
resistance, type 2 diabetes and related clustered traits, and thus for the treatment and 
prevention of these endemic disorders (Mercado et al., 2002). 
From the molecular point of view, Insulin-Resistance is caused by different metabolic 
pathways with gene-gene and gene-environment interactions. In order to begin our study, 
we selected some of the genes found within these pathways; the first selected gene was the 
Peroxisome Proliferator-Activated Receptor (PPAR2) gene, which is in turn one of the 
strongest candidate genes contributing to the susceptibility of type 2 diabetes, especially the 
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Pro12Ala polymorphism (de Dios & Frechtel, 2011). The PPAR gene is a key regulator of 
lipid metabolism and energy balance, and it is implicated in the development of insulin 
resistance and obesity. It is a member of the nuclear hormone receptor family involved in 
adipocyte differentiation and gene expression regulation, and it is a transcriptional factor 
involved in adipogenesis and regulation of adipocyte gene expression. PPAR plays a role in 
insulin signaling, insulin resistance and the development of type 2 diabetes mellitus 
(Chawla et al., 1994; Auwerx, 1999; Zhang et al., 2007) 
A splice variant of this gene contains a common amino acid polymorphism, Pro12Ala 
(carrier frequencies 8–20%, depending on the population) that, depending on the cell lines, 
reduces the ligand-induced activity of the PPAR protein by 30–50% (Altshuler et al., 2000; 
Deeb et al., 1998; Hansen et al., 2006). This missense mutation (involving a C to G 
substitution at nucleotide 34) results in the exchange of a proline for an alanine in position 
12 of the PPARγ2 protein (Yen et al., 1997). This polymorphism has been associated with a 
reduced risk of development of a type 2 diabetes mellitus (Altshuler et al., 2000; Stumvoll et 
al., 2001). Many studies have suggested that the mechanism of reduction of the risk of type 2 
diabetes mellitus by this polymorphism involves enabling greater insulin sensitivity. The 
Pro12Ala polymorphism produces a PPARγ2 protein with lower transcriptional activity 
(Deeb et al., 1998; Kang et al., 2005). The Diabetes Prevention Program (DPP) found that the 
Ala12 allele influences central obesity and that it is associated with the differences seen in 
the different treatment groups regarding polyunsaturated fatty acid intake (DPP, 2008).  
In recent years, research has identified PPARs as pivotal actors in the transcriptional control 
of the Uncoupling Protein genes (UCP) (Villarroya et al., 2007). Thus we selected this one as 
a possible second gene responsible for IR. UCP-2 are mitochondrial transporters present in 
the inner membrane of the mitochondria of several cells (Das & Elbein, 2006; Villaroya et al., 
2007). Their main function is the uncoupling of oxidative phosphorylation in the respiratory 
chain, preventing the formation of ATP from the energy released by substrate oxidation, 
and promoting its dissipation as heat.  
The UCP would be in charge of the so-called adaptive thermogenesis, i.e. the generation or 
dissipation of heat to certain stimuli, such as overeating, cold and exercise, thus regulating 
temperature and body weight. Other functions have been described, in the case of UCP-2, 
that takes part in the regulation of insulin secretion (inhibiting its secretion by lowering the 
ATP synthesis through uncoupling), in immunity, and decreased oxidative stress. Their 
presence in different tissues, together with their energy dissipating role, could be crucial in 
explaining not only the genesis of obesity, but certain co morbidities (diabetes mellitus type 
2) and their treatment.  
A common polymorphism (-866G/A) has been associated with obesity, insulin secretion, 
and type 2 diabetes (Bell et al., 2005; Freeman and Cox, 2006). In what it has to do with the 
genetic-environmental interaction, several evidences indicate a fatty acid-dependent 
activation of UCP-2. Direct analysis of regulation of the promoter of the UCP-2 gene in 
muscle cells indicated that PPARγ and their ligands induce promoter activity (Aubert et al., 
1997), while PPAR activators induce UCP-2 mRNA expression in brown adipocytes. 
Adipose tissue contains large amounts of endogenous triglycerides, which are capable of 
causing the local generation of free fatty acids after lipolysis. PPAR receptors can provide a 
mechanism for responsiveness of UCP-2 expression to intracellularly-derived fatty acid.  
Thus cross-talk between adrenergic regulation of adipose tissue lipolysis and PPAR 
induction mechanisms of UCP-2 gene expression may occur, especially in response to 
noradrenergic stimulus in brown adipocytes (Carmona et al., 1998; Villaroya et al., 2007). 
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With regard to diabetes, the overexpression of PPARγ causes up regulation of UCP-2 
expression and suppresses glucose-stimulated insulin secretion (Ito et al., 2004).  
However, there are situations where patients can, due to these genes, present the wild type 
variant and yet remain with their obesity and IR unchanged. Because of this, we selected 
another gene that may cause IR on the other metabolic pathway: IRS-1. 
IRS-1: Genetic variance in the insulin receptor substrate-1 is thought to play a key role in the 
insulin resistance that characterizes type 2 diabetes. Transfection studies have demonstrated 
that the most common IRS-1 variant, Arg972, which involves a Gly 224 Arg substitution at 
codon 972, impairs insulin signaling via the phosphatidylinositol-3 (PI3)-kinase pathway, 
and in some (but not all) studies this variant has been found with an increased frequency 
among type 2 diabetic patients (Almind et al., 1993, 1996; Imai et al., 1994; Sesti et al., 2001; 
Sigal et al., 1996; Zhang et al., 1996). Interestingly, carriers of the Arg972 substitution have 
been found to have lower fasting insulin and C-peptide levels than noncarriers (Clausen et 
al., 1995; Stumvoll et al., 2001), suggesting that this IRS-1 variant might also play a role in 
the secretory capacity of the beta-cells. Indeed, impaired insulin secretion has also been 
observed in rat insulinoma (RIN) cells overexpressing the Arg972 IRS-1 polymorphism 
(Porzio et al., 1999), in human islets naturally carrying the variant (Marchetti et al., 2002), 
and even in normal glucose-tolerant subjects with the Arg972 variant. These observations 
raise the intriguing hypothesis that genetic defects in the IRS-1/PI3 kinase pathway might 
also be involved in the inadequate insulin secretion that characterizes type 2 diabetes. More 
recent studies suggest that the Arg972 IRS-1 variant also plays a role in beta cell survival.  
The human Arg972 islets contain a significantly higher number of apoptotic cells than their 
wild-type counterparts, and they are also resistant to the antiapoptotic effects of insulin 
(Federici et al., 2003). It has been speculated that apoptosis plays a crucial role in the 
autoimmune destruction of beta cells characterizing type 1 diabetes (Mathis et al., 2001). An 
increase in apoptosis might have pathological consequences in diabetes prone individuals, 
who have an auto-reactive T-cell repertoire that may be activated by the exposed beta-cell 
antigens. The Arg972 variant of the IRS-1 seems to play a complex role in the pathogenesis 
of diabetes, affecting both peripheral insulin sensitivity and the functional capacities of the 
pancreatic beta-cells themselves. In the light of our findings, it is possible to speculate that 
the same mechanisms —in the presence of a genetically determined predisposition— might 
also result in, or contribute to, different clinical manifestations of diabetes. 
Once we have identified the genes to be analyzed, we decided to test our hypothesis: there 
are patients with a complex clinical autoimmune disease masked by insulin-resistance 
which in turn is genetically determined.  
The results of our research, although not published yet, were presented in recent meetings 
in our country and international events as the “1st Latin American Congress: 
Controversies to Consensus in Diabetes, Obesity and Hypertension [CODHy]” and the 
“XIV Latin-American Congress of Asociación Latinoamericana de Diabetes [ALAD]” 
(Fabregat et al., 2010; Farias et al., 2010; Fernández et al., 2010; Mimbacas et al., 2010; 
Reyes et al., 2010; Souto et al., 2010). 
Indeed, all patients tested (presence of HLA and positive susceptibility to type 1 diabetes 
antibody) with a body mass index >25kg/m2 and clinical diagnosis of type 2 diabetes 
were overweight or obese with mutations in one or more of the analyzed genes. Our 
results indicated that insulin resistance in patients with complex diagnosis may be 
explained by the occurrence of a mutation in one or more of the analyzed single 
nucleotide polymorphisms (SNPs).  
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5. Importance of genetics for the clinician 
In the last 15 to 20 years, clinicians have been concerned with grasping the increasing 
complexity of this disease, with a gradual worldwide increase of its prevalence that has 
turned it into a pandemic disease. The latest evidence shows that, despite correcting 
their lifestyle, we cannot always achieve good metabolic control in patients in complex 
clinical situations. 
There is a population, which is probably formed by most of our patients, with clinical 
features where their phenotype is a good reflection of their genotype; but we are finding 
with increasingly frequency clinical cases that are difficulty to classify with the current 
criteria.  
In these cases, a high percentage of patients had severe difficulties with their metabolic 
control. It is precisely here where we need to carry out a proper genetic diagnosis, and 
eventually an immunologic one, to allow us a broader view of their pathology. Several 
clinical observations and systematic studies have shown that classical type 1 diabetes, 
whether in children, late onset in adults, or individuals over 65, can coexist in the same 
individual with "classic" type 2 diabetes where insulin secretion deficiency and insulin 
resistance are detected simultaneously (Serrano Rios, 2009). This group of patients is usually 
referred to a diabetes specialist because the primary care physician cannot decide about or 
control them. Once reached this stage and after correcting the variables that affect proper 
metabolic control, such as nutritional plan and regular physical activity, we can see that 
many of these patients keep having a poor metabolic control. These patients are usually 
overweight and / or obese with a very erratic response to anti-diabetic drugs alone or in 
combination, both between them and with insulin. 
Complying with the algorithms, we almost always end up giving insulin to our patients, but 
in many cases this is probably done too late. This was analyzed by many authors that 
described as final: “therapeutic inertia”. They are usually described as patients with a poor 
adherence to the treatment plan. Also, on average they start insulin treatment before the 
classical diabetes type 2 patients.  
Thus, we are planning to deepen into genetic typing, in order to see if it may help us to 
understand the etiopathogenesis of these patients, and why they do not have the expected 
response to the drug treatment. 
As stated above, these patients surprisingly had a genotype that does not agree with their 
phenotype. This was what allowed us as clinicians to begin to understand these facts and to 
find an explanation (albeit partial) of the poor outcome of each patient. 
What are the issues that the clinician should consider for further study of certain patients? 
a. Obese patients showing good response to insulin during intercurrence: many of these 
patients had an intercurrent disease, and with the temporary insulin treatment they 
achieved a good control (especially in early stages of diagnosis) that may be 
explained by an improvement in glucotoxicity and / or moderate insulinopenia.  In 
these patients the insulin will be removed based on these myths: (1) Insulin is 
"ineffective"; (2) Insulin injection increases cardiovascular diseases and 
hyperinsulinemia; and (3) Insulin causes weight gain. The reluctance we see in these 
patients insulin is based on misguided or questionable in view of the genetic results 
we are finding and the matching clinical trials.  
b. Poor response to insulin sensitizers: in particular thiazolidinedione but also biguanides. 
c. Poor response to secretagogues: it is usually attributed to glucotoxicity, but how much 
influence does drug response have? 
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d. Obese patients without dyslipidemia or other elements of metabolic syndrome. 
e. Overweight or obese type 2 diabetes patients with hypoglycemia episodes, especially 
at night. 
f. Type 2 Diabetic patients with microangiopathic complications preceding or 
concomitant to the macrovascular complications. 
Already, Nolan and Murphy (2001) posed an approach to the phenotypic and metabolic 
characterization of insulin-resistant patients, impaired glucose tolerance, or type 2 diabetes, 
and the use of glutamic acid decarboxylase antibodies (GADA), genetic markers, and 
models to estimate the insulin-resistance should be considered. These authors discuss the 
utility of using genetic markers based on population studies for type 2 diabetes mellitus. In 
what it has to do with the poor response to treatment, we must remember that both 
therapeutic inefficiency and drug toxicity, which have been seen in some individuals, have 
been frequently observed. Due to the presence of some drug metabolizing enzymes, drugs 
can participate as inhibitors or inducers of these enzymes, thereby their variation in activity 
between individuals. This variability in enzyme activity may reflect the existence of 
mutations in their genes. 
6. Conclusion: What is happening? 
The above mentioned points will lead us to review the different mechanisms that may have 
taken place in the evolutionary processes leading to the current status of this disease. We 
will consider some possible situations. 
a. Researchers are considering the way natural selection is currently operating in 
humans. The concept of “the survival of the strongest individual” perhaps is no 
longer valid in the 21st century. Quintana Murci et al. (2007), at the Pasteur Institute 
(Paris), have looked for answers regarding the mechanisms of human evolution by 
comparing whole genomes of different populations. They analyzed more than 2.8 
million genetic markers in different populations from different ethnic groups 
collected in the HAPMAP project. They found that 582 genes were subject to “strong 
selective pressures” during the last 60,000 to 10,000 years. Some of these genes are 
strongly associated to external features (e.g.: hair, skin color); others are to the 
response to pathogenic agents or drugs; and others to diseases with different 
incidences between populations, like diabetes, obesity, or hypertension. Barreiro 
pointed out that ”it is the first time that it can be demonstrated, concerning the whole 
genome that natural selection participates in the differentiation of the populations” 
This work is not only useful to satisfy our curiosity, but also to aid in the 
identification of genes implied in different diseases (Barreiro et al., 2005; 2008). 
Well defined since the XV century, clinical knowledge on diabetes gradually increased, and 
in the end two major distinct types of this pathology were described (1 and 2). In order to 
understand the current increase of chronic diseases, it is necessary to consider the important 
relationship between human feeding and human evolution. The regular offer of food that 
seemed to help human evolution so greatly in the past is also generating a great amount of 
diseases and their corresponding incapacities (like hemiplegics, aphasia, amputations, etc.). 
This fact is a true evolutionary paradox (Insua & Fuks, 2003). 
Initially, we must consider the importance of the neutralization of positive selective pressure 
introduced by the availability of nutrients as consequence of human civilization. A good 
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example of the relationship between nutritional factors, diabetes, and population genetics is 
Szathmary’s hypothesis (Marrodán, 2000) for explaining the high incidence of diabetes in 
several Amerindian populations (USA and Canada), either in reservations or in those 
adapted to western life. 
Diabetes is a genetic-based disease whose manifestation is partly favored by excessive 
carbohydrate consumption. Possibly, several individuals with a specific genotype would 
produce insulin faster when faced with higher glucose levels than others; and they would 
also store this glucose as glycogen or fat more efficiently. This genotype would have been 
positively selected in a nutritional environment where periods of abundant or shortage of 
foods oscillate in a critical form. But this capacity for a faster answer to carbohydrate 
stimulus has a biological cost when food intake is constant. Under this situation, genes 
increasing insulin production are no longer beneficial to the individual because their carriers 
become obese, exhausting the physiological capacity of the pancreas, and leading to the 
subsequent development of diabetes (Marrodán, 2000; Harris, 2002). Variations in diabetes 
or obesity genes imply that adaptation to fasting was also an important selective agent. 
Quintana-Murci et al. (2007) pointed out that insulin-regulating genes have been positively 
selected. Thus, for instance, the ENPP1 gene has a mutation protecting against obesity and 
type II diabetes. This variant is present in 90% of non-African individuals and it is almost 
absent in African ones.  
The susceptible genotype may have been selected in these populations because unusually 
frequent fasting periods may have taken place during the initial colonization of 'new 
worlds'. The abovementioned non-insulin dependent diabetes mellitus has shown a strong 
genetic component that may include a 'thrifty' genotype(s) (Neel 1962; Zimmet et al., 1990).  
The 'thrifty' genotype(s) may have once allowed founding populations to survive both 'feast' 
and 'famine' conditions for several generations. Individuals carrying these genes would 
have had an increased efficiency for energy extraction (nutrition) from environmental scarce 
resources. During times of abundance those individuals with this predisposition would 
store more energy than those lacking it. When the progress of human civilization assured 
continuous fat-rich and fiber-poor diets, and a sedentary lifestyle, the 'thrifty' genotype(s) 
became disadvantageous, leading to obesity, increased insulin resistance, beta cell 
misbalance, and finally diabetes (Wendorf, 1991; 1992).  
What was a selective advantage in past environments is currently, for most people in 
industrialized countries, an undesired condition. The result is obesity, diabetes, and the 
metabolic syndrome. For many years, diabetes was considered as a lethal or near-fatal 
disease by death simply by complications or by difficulties in the reproductive stages, both 
for men and women. More recently —the use of insulin is a landmark in this subject— 
reproductive problems and some of their related complications have been solved.  
In conclusion, evolutionary or Darwinian medicine considers that many contemporary 
diseases are associated to incompatibility between current human lifestyles and 
environments, and those under which human biology was shaped. As the observed 
difference between the incremental rates of both civilization and evolution is so great, most 
human evolutionary changes took place when our ancestors were gatherer-hunters. Thus, 
many characteristics and conducts that had adaptive value in the past may currently have 
non-adaptive value. Medicine has always tried to improve and look for the patient’s cure. It 
really improved people’s health, but in this process populational issues that are beyond the 
epidemiologic point of view were overlooked. This medical conduct may be explained by 
www.intechopen.com
 
Diabetes Type 1 and 2: What is Behind a Classification? 
 
297 
the lack of information, or misinterpretation, of the importance of the genetic components of 
the disease. But this disregarding could be considered also as having iatrogenic elements: 
we improve the current patient’s quality of life, but on the other hand we hamper that of 
future persons. This process implies the emergence of currently unknown entities. New 
discoveries have allowed life extension for affected people, with the subsequent appearance 
of new pathological complications that were not seen before simply because affected 
individuals passed away before their onset. 
b. Are we witnessing a new type of diabetes, called “double o hybrid” by some authors? 
We believe that the phenomenon we are watching is simply another expression of the 
multifactorial nature of this disease. When we analyze populations with an ethnic 
mixture or of different ethnic origins, we begin to get a glimpse of the products of 
genetic admixture. This leads us to find a higher proportion of problematic patients that 
are difficult to classify because, when examining their phenotype, they are affected by 
certain genes that are masked by others. Hence, we can see families where, according to 
traditional classification, both entities (type 1 and type 2) coexist. This fusion would be 
associated with a new and intermediate phenotype (Tuomi, 2005). There are a few 
studies identifying patients where both type of diabetes overlap (Libman &. Becker, 
2003; Pozzilli & Guglielmi, 2009); moreover, Pozzilli and Gugliemi (2007) place this 
entity in the middle of the double “rainbow” (made up of type 1 and type 2 diabetes).   
The “accelerator hypothesis” is a theory that shares this vision. It is a singular, unifying 
concept, which states that type 1 and type 2 diabetes are the same insulin-resistance disorder 
set against different genetic backgrounds. This hypothesis does not deny the role of 
autoimmunity, only its primacy in the process. It distinguishes type 1 and 2 diabetes only by 
tempo, the faster tempo reflecting the (inevitably) earlier presentation in the more 
susceptible genotype (Wilkin, 2009).  
Recognition that susceptibility arises through the combination of multiple genetic pathways 
influencing hazardous factors in a nonlinear manner suggests that a 'decanalization' process 
contributes to the epidemic nature of common genetic diseases. The evolution of the human 
genome, combined with a marked environmental and cultural perturbation in the past two 
generations, might lead to the uncovering of cryptic genetic variations that are a major 
source of disease susceptibility (Gibson, 2009).  
This would be also favored by others processes such as an increase of life expectancy and 
fertility of affected individuals, the globalization phenomena, and increased admixture of 
different ethnic groups when compared with the past. The last phenomenon is clearly seen 
in Latin America and mainly in the Uruguayan population as it was stated above.  
Regardless of all the arguments presented in this chapter, we think that it is extremely 
important to introduce the genetic risk profile into the present diabetes classification criteria. 
This will clearly improve our capability of distinguishing between different types of 
diabetes or specific presentations. 
The effects of genetic traits in diabetes had been studied for decades, but few consistent risk 
factors have been well established. Currently, most of large scale studies on candidate genes 
do not combine the analysis of both types of diabetes. Establishing the association between 
genotype and phenotype would allow a deeper insight into the pathogenesis of the disease. 
Screening of associated anomalies and the possibility of anticipating future outcomes would 
be consequently improved. 
While for many countries, especially in Latin-America, individual genetic diagnosis can be 
very expensive to implement, we must realize that we are facing a multifactorial disease. 
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Thus, although classifications may be useful, they only have relative value. We must keep 
an open mind to the fact that there are patients that do not fall in any of them, and we must 
remember that genetics is at the base of diabetes, as there are multiple genes that interact 
both with the environment and between them. These interactions can result in a somewhat 
"liar" phenotype. In the preceding sections we saw how mutations in a few genes associated 
to insulin resistance may mask the presence and/or action of genes causing autoimmune 
disorders. Moreover, if we take into account the modifications observed with genome 
scanning, where there are millions of Single Nucleotide Polymorphisms, it is virtually 
impossible to make a phenotype-based classification. 
Although we are aware that understanding the pathogenesis of hyperglycemia or the basis 
for an effective treatment may be deemed as more important than knowing the type of 
diabetes we are dealing with, we are currently persuaded that the distinguishing between 
different types or presentation forms of diabetes based on genetic information is an 
important task that has turned into our great challenge.  
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